GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Gross Margin %

Taiko Pharmaceutical Co (TSE:4574) Gross Margin % : 59.27% (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Taiko Pharmaceutical Co's Gross Profit for the three months ended in Jun. 2024 was 円879 Mil. Taiko Pharmaceutical Co's Revenue for the three months ended in Jun. 2024 was 円1,483 Mil. Therefore, Taiko Pharmaceutical Co's Gross Margin % for the quarter that ended in Jun. 2024 was 59.27%.


The historical rank and industry rank for Taiko Pharmaceutical Co's Gross Margin % or its related term are showing as below:


TSE:4574's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 47.795
* Ranked among companies with meaningful Gross Margin % only.

Taiko Pharmaceutical Co had a gross margin of 59.27% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Taiko Pharmaceutical Co was 0.00% per year.


Taiko Pharmaceutical Co Gross Margin % Historical Data

The historical data trend for Taiko Pharmaceutical Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Gross Margin % Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.42 69.01 70.82 25.62 21.39

Taiko Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.03 38.41 46.15 58.02 59.27

Competitive Comparison of Taiko Pharmaceutical Co's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's Gross Margin % falls into.


;
;

Taiko Pharmaceutical Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Taiko Pharmaceutical Co's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=1078 / 5040
=(Revenue - Cost of Goods Sold) / Revenue
=(5040 - 3962) / 5040
=21.39 %

Taiko Pharmaceutical Co's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=879 / 1483
=(Revenue - Cost of Goods Sold) / Revenue
=(1483 - 604) / 1483
=59.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Taiko Pharmaceutical Co  (TSE:4574) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Taiko Pharmaceutical Co had a gross margin of 59.27% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Taiko Pharmaceutical Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co Headlines

No Headlines